CN1665538A - 血栓烷a2受体拮抗剂和cox－2抑制剂的药物组合 - Google Patents

血栓烷a2受体拮抗剂和cox－2抑制剂的药物组合 Download PDF

Info

Publication number
CN1665538A
CN1665538A CN038161303A CN03816130A CN1665538A CN 1665538 A CN1665538 A CN 1665538A CN 038161303 A CN038161303 A CN 038161303A CN 03816130 A CN03816130 A CN 03816130A CN 1665538 A CN1665538 A CN 1665538A
Authority
CN
China
Prior art keywords
cox
inhibitor
thromboxane
patient
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN038161303A
Other languages
English (en)
Chinese (zh)
Inventor
H·R·布伦纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BMRA Corp BV
Original Assignee
BMRA Corp BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BMRA Corp BV filed Critical BMRA Corp BV
Publication of CN1665538A publication Critical patent/CN1665538A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN038161303A 2002-07-09 2003-07-03 血栓烷a2受体拮抗剂和cox－2抑制剂的药物组合 Pending CN1665538A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39426802P 2002-07-09 2002-07-09
US60/394,268 2002-07-09

Publications (1)

Publication Number Publication Date
CN1665538A true CN1665538A (zh) 2005-09-07

Family

ID=30115701

Family Applications (1)

Application Number Title Priority Date Filing Date
CN038161303A Pending CN1665538A (zh) 2002-07-09 2003-07-03 血栓烷a2受体拮抗剂和cox－2抑制剂的药物组合

Country Status (7)

Country Link
US (2) US20050020657A1 (enExample)
EP (1) EP1519753A1 (enExample)
JP (1) JP2005533830A (enExample)
CN (1) CN1665538A (enExample)
AU (1) AU2003244913A1 (enExample)
CA (1) CA2491848A1 (enExample)
WO (1) WO2004004776A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106188245A (zh) * 2016-08-30 2016-12-07 苏州普罗达生物科技有限公司 血栓烷a2抑制剂多肽及应用
CN111728970A (zh) * 2014-05-16 2020-10-02 坎伯兰医药品股份有限公司 用伊非曲班治疗心脏纤维化的组合物和方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
CA2534316A1 (en) * 2003-08-07 2005-02-24 B.M.R.A. Corporation B.V. Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxygenase-1
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
EP1863534A1 (en) * 2005-03-23 2007-12-12 Boehringer Ingelheim International GmbH Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a cox-2 inhibitor
US20070037797A1 (en) * 2005-08-15 2007-02-15 Hellstrom Harold R Method of reducing the risk of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which favor CV events
EP2144999A4 (en) * 2007-05-03 2010-06-16 Portola Pharm Inc USE OF TP MODULATORS TO TREAT HEART CIRCULAR ILLNESSES IN ASPIRINSENSITIVES AND OTHER POPULATIONS
US8188267B2 (en) * 2008-02-13 2012-05-29 Eastman Chemical Company Treatment of cellulose esters
PL4378443T3 (pl) 2009-10-12 2025-09-08 Boehringer Ingelheim Vetmedica Gmbh Pojemniki na kompozycje zawierające meloksykam
CA2791805A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
CN114569608A (zh) * 2015-06-30 2022-06-03 坎伯兰医药品股份有限公司 Aerd/哮喘中的血栓烷受体拮抗剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK471479A (da) * 1978-12-13 1980-06-14 Pfizer Fremgangsmaade til fremstilling af imidazolderivater og salte deraf
US5100889A (en) * 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
GB9220137D0 (en) * 1992-09-23 1992-11-04 Pfizer Ltd Therapeutic agents
JPH0753505A (ja) * 1992-10-01 1995-02-28 Hokuriku Seiyaku Co Ltd ベンゼンスルホンアミド誘導体及びその用途
US5605917A (en) * 1994-12-22 1997-02-25 Bristol-Myers Squibb Company Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog
US6586458B1 (en) * 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
CA2407469A1 (en) * 2000-05-15 2001-11-22 Merck Frosst Canada & Co. Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
WO2003035063A1 (en) * 2001-10-25 2003-05-01 Dinesh Shantilal Patel Novel preparation of selective cyclooxygenase ii inhibitors
AU2003247622A1 (en) * 2002-06-27 2004-01-19 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111728970A (zh) * 2014-05-16 2020-10-02 坎伯兰医药品股份有限公司 用伊非曲班治疗心脏纤维化的组合物和方法
CN106188245A (zh) * 2016-08-30 2016-12-07 苏州普罗达生物科技有限公司 血栓烷a2抑制剂多肽及应用

Also Published As

Publication number Publication date
CA2491848A1 (en) 2004-01-15
AU2003244913A1 (en) 2004-01-23
US20080113973A1 (en) 2008-05-15
EP1519753A1 (en) 2005-04-06
US20050020657A1 (en) 2005-01-27
WO2004004776A1 (en) 2004-01-15
JP2005533830A (ja) 2005-11-10

Similar Documents

Publication Publication Date Title
US20080113973A1 (en) Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2
ES2380752T3 (es) Agente profiláctico y/o terapéutico para hiperlipidemia
JPH01503539A (ja) 非鎮静抗ヒスタミン薬を含んでなる咳／風邪用混合物
US20100221337A1 (en) Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist
US9662315B2 (en) Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
CN100376245C (zh) 结合有泰妥拉唑与消炎剂的药物组合物
CN1210465A (zh) 治疗方法和药物组合物
JP2005533830A5 (enExample)
WO2002083119A1 (en) Pharmaceutical composition comprising ibuprofen and prochlorperazine
AU724526B2 (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
CA2691467A1 (en) Cholesterol lowering drug combination
HK1080750A (en) Pharmaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor
JP2011525479A (ja) 非ステロイド性抗炎症性化合物と降圧化合物とを組み合わせた製剤処方及びその使用方法
Jones et al. Clinical pharmacology: traditional NSAIDs and selective COX-2 inhibitors
JPS60500016A (ja) 鎮痛薬組成物類
EP0971714B1 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
WO2007041499A2 (en) Cox inhibitor and nicotinic acid compositions and methods
US20050059741A1 (en) Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-1
RU2182016C2 (ru) Спазмолитическая композиция, способ получения спазмолитической композиции
Coppens Intravenous Non-steroidal Anti-inflammatory Agents.
Pain Non-opioid Analgesics
EA050266B1 (ru) Фармацевтическая композиция, включающая 1-(3-циано-1-изопропилиндол-5-ил)пиразол-4-карбоновую кислоту
US20020058688A1 (en) Method of using cyclooxegenase-2 inhibitors in the treatment and prevention of dementia
Williams et al. There May Be a Way to Say′ NO′ to Gastric Injury Associated with the Combined Use of Aspirin and Cyclooxygenase‐2 Inhibitors
BR102018007757B1 (pt) Composição farmacêutica, processo de fabricação, uso

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1080750

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1080750

Country of ref document: HK